XTX Topco Ltd Acquires New Position in Repligen Co. (NASDAQ:RGEN)

XTX Topco Ltd bought a new position in Repligen Co. (NASDAQ:RGEN) during the fourth quarter, Holdings Channel.com reports. The institutional investor bought 9,640 shares of the biotechnology company’s stock, valued at approximately $1,388,000.

A number of other institutional investors have also bought and sold shares of the business. UMB Bank n.a. increased its holdings in shares of Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after purchasing an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in Repligen in the 4th quarter valued at $216,000. Van ECK Associates Corp increased its stake in shares of Repligen by 7.8% in the 4th quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company’s stock worth $6,078,000 after acquiring an additional 3,066 shares during the last quarter. Stephens Investment Management Group LLC raised its holdings in shares of Repligen by 7.4% during the 4th quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company’s stock worth $77,267,000 after acquiring an additional 37,057 shares during the period. Finally, Sanctuary Advisors LLC acquired a new position in shares of Repligen during the 3rd quarter valued at about $233,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on RGEN shares. JPMorgan Chase & Co. raised their price objective on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group began coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Evercore ISI began coverage on Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Finally, StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday, April 4th. Seven investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $178.64.

Insider Activity at Repligen

In other news, Director Margaret Pax purchased 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average price of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares of the company’s stock, valued at $157,169.67. The trade was a 31.53 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Stock Up 3.6 %

Shares of NASDAQ:RGEN opened at $127.26 on Tuesday. The firm’s 50-day moving average is $142.43 and its two-hundred day moving average is $146.19. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. Repligen Co. has a 1 year low of $102.97 and a 1 year high of $182.52. The firm has a market capitalization of $7.15 billion, a PE ratio of -249.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.27.

Repligen (NASDAQ:RGEN) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. Analysts predict that Repligen Co. will post 1.72 EPS for the current year.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.